Heidelberg Pharma AG - ESG Rating & Company Profile powered by AI
This ESG rating covers seventeen United Nations SDGs including: 'Good Health & Wellbeing', 'Climate Action' and 'Partnerships for the Goals'. The analysis of Heidelberg Pharma AG uses data points from across the web as well as from public disclosures by Heidelberg Pharma AG. The analysis of Heidelberg Pharma AG is prepared by All Street Sevva using cutting edge artificial intelligence.
Heidelberg Pharma AG in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.1; made up of an environmental score of 5.3, social score of 8.0 and governance score of 8.0.
7.1
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 217 | Takara Bio Inc | 7.2 | High |
| 217 | Ultragenyx Pharmaceutical Inc | 7.2 | High |
| 224 | Heidelberg Pharma AG | 7.1 | High |
| 224 | Celularity Inc | 7.1 | High |
| 224 | Bilcare Ltd | 7.1 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Heidelberg Pharma AG have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Heidelberg Pharma AG disclose current and historical energy intensity?
Sign up for free to unlockDoes Heidelberg Pharma AG report the average age of the workforce?
Sign up for free to unlockDoes Heidelberg Pharma AG reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Heidelberg Pharma AG disclose its ethnicity pay gap?
Sign up for free to unlockDoes Heidelberg Pharma AG disclose cybersecurity risks?
Sign up for free to unlockDoes Heidelberg Pharma AG offer flexible work?
Sign up for free to unlockDoes Heidelberg Pharma AG have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Heidelberg Pharma AG disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Heidelberg Pharma AG conduct supply chain audits?
Sign up for free to unlockDoes Heidelberg Pharma AG disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Heidelberg Pharma AG conduct 360 degree staff reviews?
Sign up for free to unlockDoes Heidelberg Pharma AG disclose the individual responsible for D&I?
Sign up for free to unlockDoes Heidelberg Pharma AG disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Heidelberg Pharma AG disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Heidelberg Pharma AG disclose water use targets?
Sign up for free to unlockDoes Heidelberg Pharma AG have careers partnerships with academic institutions?
Sign up for free to unlockDid Heidelberg Pharma AG have a product recall in the last two years?
Sign up for free to unlockDoes Heidelberg Pharma AG disclose incidents of discrimination?
Sign up for free to unlockDoes Heidelberg Pharma AG allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Heidelberg Pharma AG issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Heidelberg Pharma AG disclose parental leave metrics?
Sign up for free to unlockDoes Heidelberg Pharma AG disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Heidelberg Pharma AG disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Heidelberg Pharma AG disclose the pay ratio of women to men?
Sign up for free to unlockDoes Heidelberg Pharma AG support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Heidelberg Pharma AG disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Heidelberg Pharma AG reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Heidelberg Pharma AG involved in embryonic stem cell research?
Sign up for free to unlockDoes Heidelberg Pharma AG disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Heidelberg Pharma AG disclose its waste policy?
Sign up for free to unlockDoes Heidelberg Pharma AG report according to TCFD requirements?
Sign up for free to unlockDoes Heidelberg Pharma AG disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Heidelberg Pharma AG disclose energy use targets?
Sign up for free to unlockDoes Heidelberg Pharma AG disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Heidelberg Pharma AG have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Heidelberg Pharma AG
These potential risks are based on the size, segment and geographies of the company.
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for tumors; and HDP-XX for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; TAK-ATACs for oncology; and TLX250-CDx, a diagnostic antibody for imaging diagnostics of renal cancer in Phase III trials; urothelial carcinoma or bladder cancer in Phase I study; and triple-negative breast cancer in Phase II study. In addition, the company develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II/III study to treat COVID-19, as well as for the treatment of advanced cholangiocarcinoma; and LH011 for pancreatic cancer. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.